Brantley, Kristen D
Douglas, Teresa D
Singh, Rani H
Funding for this research was provided by:
BioMarin Pharmaceutical (Independent Investigator Award)
Clinical and Translational Science Award program, National Institutes of Health (PHS Grant UL1 RR025008)
Article History
Received: 22 November 2017
Accepted: 2 October 2018
First Online: 30 October 2018
Ethics approval and consent to participate
: Protocol reviewed and approved by Emory University’s institutional review board (IRB). All patients enrolled in the study completed a signed consent form during an initial screening visit. Study procedures and details of consent were explained to potential participants prior to signed consent to enroll in the study. Legal guardians provided signed consent for children under age 16, and the child gave oral consent. For participants age 16 and 17, signed consent from both the legal guardian and child was required. For 18 years and older, signed consent just from the participant was required for enrollment. Participants were free to refuse any procedure in the protocol and withdraw their participation at any time during the study.
: I, Kristen Brantley give my consent for publication of the information in this manuscript.I, Teresa D. Douglas PhD, give my consent for publication of the information in this manuscript.I, Rani H. Singh PhD RD, give my consent for publication.
: Independent investigator sponsored trial with partial funding provided by BioMarin Pharmaceutical Inc.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.